N/A N=878 Pre-engraftment Cytomegalovirus DNAemia
CMV DNAemia Pre-engraftment
Primary: Time to Engraftment (Days) Stratified by CMV DNaemia Occurring Before or After Neutrophil's Engraftment — 17; 19 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=239 Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
Cytomegalovirus Infection
Primary: Number of Participants With Clinically Significant CMV Infection — 13; 4; 6; 4 Participants
Phase 2 N=160 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
Phase 4 N=40 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Number of Patients With Late CMV Disease — 0; 0 Participants
Phase 3 N=452 A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
CMV
Primary: Number of Participants With Clinically Significant CMV Infection Through Week 24 Post-Transplant — 155; 78 Participants
Phase 4 N=205 CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
Cytomegalovirus Infection
Primary: Incidence of Cytomegalovirus (CMV) Disease. — 9; 20 participants — p=0.0396
N/A N=172 Dried Blood Spot Testing of CMV Detection in HCT Recipients
Cytomegalovirus Infection
Primary: The Number of Participants Who Have Completed >90% of Their Recommended Cytomegalovirus (CMV) Monitoring Tests in the DBS and Control Arms in the ITT Population — 27; 15…
Phase 3 N=299 A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation
Cytomegalovirus Infections
Primary: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months — 14.1; 42.6 percentage of participants
Phase 2 N=58 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Phase 2 N=137 ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Transplantation Infection · Epstein-Barr Virus Infections · Cytomegalovirus Infections
Primary: Compare Incidence, Duration and Magnitude of CMV and EBV Viremia in Kidney Transplant Recipients Receiving valA vs. valG. — 16; 20; 8; 4 Participants
Phase 3 N=326 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
Phase 2 N=77 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
CMV Infection · Persistent CMV Viremia
Primary: Complete Response — 20; 57 Participants
N/A N=111 Evaluation of the Artus® CMV PCR Test
Cytomegalovirus Infections
Primary: a) CMV Viral Load — 100; 97.6; 86.36; NA percentage of agreement
N/A N=82 Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants
N/A N=14 An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
Cytomegalovirus Infections
Primary: Proportion of Patients Developing Cytomegalovirus (CMV) Disease Within 6 Months of Liver Transplantation Under Valcyte Prophylaxis — 3 participants
Phase 2 N=61 Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Leukemia · Lymphoma
Primary: Number of Participants With Adverse Events — 1; 31; 1; 22 Participants
Phase 2 N=29 CMX001 in Post-transplant Patients With BK Virus Viruria
Viruria
Primary: Number of Adverse Events in Post-Transplant Patients With BK Virus Viruria — 1; 1; 1; 2 Participants
Phase 2 N=4 ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
Viral Infection
Primary: Number of Participants With a DLT — 0; 0; 0; 3 Participants
Phase 2 N=1 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
N/A N=800 A Study of Cytomegalovirus Disease Epidemiology in Pediatric and Adult Liver Transplant Recipients in China
Cytomegalovirus (CMV) Infections Among Children and Adult Liver Transplantation Patients in China
Primary: Number of Participants With Clinically Significant CMV Reactivation or CMV Disease — 62; 89; 78; 32 Participants
Phase 4 N=70 Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
Transplant Complication · CMV
Primary: Clinical Significant Leukopenia — 8; 1 Participants
Phase 2 N=38 Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants
Phase 4 N=236 Letermovir Use in Heart Transplant Recipients
Cytomegalovirus Disease · Cytomegalovirus Infections · Heart Transplant Infection
Primary: Proportion of Patients With Neutropenia Compared to Historical Controls — 0; 30 Participants — p=0.02
Phase 4 N=57 A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Kidney Transplantation, Cytomegalovirus Infections
Primary: Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Withdrawal Due to AEs — 56; 41; 6 Participants
Phase 4 N=13 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Infection in Solid Organ Transplant Recipients
Primary: Area Under the Curve (AUC) — 21.0 mcg∙h/mL
Phase 3 N=136 Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Cytomegalovirus Infections
Primary: Incidence of CMV End Organ Disease — 21; 1 participants
Phase 2 N=87 A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Cytomegalovirus Disease
Primary: Incidence of CMV Disease or CMV Viremia — 29; 9; 26 Participants
Phase 3 N=570 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
Prevention of CMV Infection or Disease
Primary: Percentage of Participants With Clinically-significant CMV Infection up to Week 24 Post-transplant — 37.5; 60.6 Percentage of participants — p=<0.0001
Phase 3 N=96 Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Cytomegalovirus Infection
Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants
Phase 1 N=11 Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants